Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer
Author：Shan-Shan Hong, Ming-Xing Zhang, Meng Zhang, Yi Yu, Jun Chen, Xiao-Yan Zhang, Cong-Jian Xu 《Drug Delivery》
ABSTRACTS
The distinct hormone molecules and receptors, such as follicle-stimulating hormone receptor (FSHR) in ovarian cancer, provide opportunities for more precisely targeted therapy. We previously developed FSHR-mediated nanoparticles and found that FSH peptides on the surface of nanoparticles improved the delivery of short interfering RNA (siRNA) into ovarian cancer cells. However, the high toxicity of the nanoparticles and the transient silencing of the siRNA in vivo limited further study. Here, we developed FSH peptide-conjugated nanoparticles with an increased amount of polyethylene glycol (PEG) grafting and encapsulated short hairpin RNA (shRNA) to silence the target gene, growth-regulated oncogene α (gro-α).
KEY WORDS
Ovarian carcinoma, targeted therapy, follicle-stimulating hormone, growth-regulated oncogene α, short hairpin RNA
SCREENSHOT
📷
RELATED PRODUCTS
FSH β 33-53 peptides (YTRDLVYKDPARPKIQKTCTF; China Peptides Co. Ltd., Shanghai, China)
CHAINING
https://www.tandfonline.com/doi/abs/10.1080/10717544.2018.1440667
Comments